(Q34576803)

3 August 2017

1 reference

title

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. (English)

1 reference

3 August 2017

1 reference

1 reference

1

Michelle A Fanale

1 reference

3 August 2017

Anas Younes

2

1 reference

3 August 2017

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

67

1 reference

3 August 2017

333-350

1 reference

3 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767030-00002

3 August 2017

0 references

cites work

B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules

1 reference

12 December 2020

Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies

1 reference

12 December 2020

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

1 reference

12 December 2020

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

1 reference

12 December 2020

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

12 December 2020

Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumo

1 reference

12 December 2020

BAFF and the regulation of B cell survival

1 reference

12 December 2020

To die or not to die--the quest of the TRAIL receptors

1 reference

12 December 2020

BAFF AND APRIL: a tutorial on B cell survival

1 reference

12 December 2020

The TNF family members BAFF and APRIL: the growing complexity

1 reference

12 December 2020

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

1 reference

12 December 2020

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

12 December 2020

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

12 December 2020

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

12 December 2020

1 reference

12 December 2020

Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

1 reference

12 December 2020

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

12 December 2020

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

1 reference

12 December 2020

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

1 reference

12 December 2020

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

12 December 2020

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

1 reference

12 December 2020

Novel immune-based treatment strategies for chronic lymphocytic leukemia

1 reference

12 December 2020

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

12 December 2020

Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL.

1 reference

12 December 2020

In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease

1 reference

12 December 2020

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

1 reference

12 December 2020

Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

1 reference

12 December 2020

CD2 signaling in T cells involves tyrosine phosphorylation and activation of the Tec family kinase, EMT/ITK/TSK.

1 reference

12 December 2020

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

12 December 2020

The uncertain glory of APRIL.

1 reference

12 December 2020

The B7 and CD28 receptor families

1 reference

12 December 2020

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

12 December 2020

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.

1 reference

12 December 2020

CD30 ligand in lymphoma patients with CD30+ tumors

1 reference

12 December 2020

Receptor-mediated choreography of life and death.

1 reference

12 December 2020

B7-mediated costimulation and the immune response

1 reference

12 December 2020

Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

1 reference

12 December 2020

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

1 reference

12 December 2020

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

12 December 2020

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

1 reference

12 December 2020

The biology of VEGF and its receptors

1 reference

12 December 2020

Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions

1 reference

12 December 2020

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

1 reference

12 December 2020

Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype

1 reference

12 December 2020

In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation

1 reference

12 December 2020

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

12 December 2020

Therapeutic monoclonal antibodies in oncology.

1 reference

12 December 2020

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

12 December 2020

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

12 December 2020

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

12 December 2020

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

1 reference

12 December 2020

Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30.

1 reference

12 December 2020

Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease

1 reference

12 December 2020

1 reference

12 December 2020

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.

1 reference

12 December 2020

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

12 December 2020

Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival

1 reference

12 December 2020

Survival and proliferation factors of normal and malignant plasma cells

1 reference

12 December 2020

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

1 reference

12 December 2020

Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue

1 reference

12 December 2020

From angiogenesis to lymphangiogenesis

1 reference

12 December 2020

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

1 reference

12 December 2020

Mouse CD20 expression and function

1 reference

12 December 2020

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

1 reference

12 December 2020

The dynamics of life and death of malignant lymphocytes

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease

1 reference

12 December 2020

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

1 reference

12 December 2020

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Antibody conjugates and therapeutic strategies

1 reference

12 December 2020

Death receptors: signaling and modulation

1 reference

12 December 2020

The biology of CD20 and its potential as a target for mAb therapy

1 reference

12 December 2020

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

12 December 2020

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

12 December 2020

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

10.2165/00003495-200767030-00002

Identifiers

DOI

1 reference

PubMed ID

17335294

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

17335294